TerminatedPhase 3NCT04925960
Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG
Studying PMM2-CDG
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Maggie's Pearl, LLC
- Principal Investigator
- Eva Morava-Kozicz, MD, PhD, M.DMayo Clinic
- Intervention
- Epalrestat(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 2-17 years · All sexes
- Timeline
- 2022 – 2025
Study locations (1)
- Mayo Clinic, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04925960 on ClinicalTrials.govOther trials for PMM2-CDG
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06892288A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDGGlycomine, Inc.
- ENROLLING BY INVITATIONPHASE2NCT06657859Open-Label Extension Study to Assess GLM101 in PMM2-CDG PatientsGlycomine, Inc.
- ACTIVE NOT RECRUITINGNCT03173300Natural History Study Protocol in PMM2-CDG (CDG-Ia)Glycomine, Inc.